Elizabeth M. Poole
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Elizabeth M. Poole has a total of 405 co-authors. Here are the top co-authors by number of shared publications:
- Shelley S. Tworoger
Division of Oncological Sciences and the Knight Cancer Institute Oregon Health & Science University Portland Oregon USA
15 shared publications - Bette J. Caan
Division of Research, Kaiser Permanente Northern California, Oakland, USA
9 shared publications Karen W. Makar
Fred Hutchinson Cancer Research Center, Seattle, USA
8 shared publications- John D. Potter
Fred Hutchinson Cancer Center 7 , Seattle, Washington
6 shared publications Martha L. Slattery
Department of Medicine, School of Medicine, University of Utah, Salt Lake City, USA
6 shared publicationsCornelia M. Ulrich
National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany
5 shared publications
Latest Publications
- Open Access
- 9 June 2026
- Published by Taylor & Francis in Future Neurology
- Vol. 21 (1)
The clinical and economic burden of idiopathic hypersomnia: a plain language summary of publication
- 9 June 2026
- Published by Taylor & Francis in Future Neurology
- Vol. 21 (1)
Open AccessThe clinical and economic burden of idiopathic hypersomnia: a plain language summary of publication
- Open Access
- 1 August 2025
- Published by Taylor & Francis in Nature and Science of Sleep
- Vol. ume 17, 1809-1823
The Clinical and Economic Burden of Idiopathic Hypersomnia and Narcolepsy: A United States Claims-Based Analysis
Purpose: Idiopathic hypersomnia and narcolepsy are similar but distinct sleep disorders. This study evaluated the clinical and economic burden experienced by individuals with either condition. Patients and Methods: Merative™ MarketScan® Research Databases claims were analyzed (study period, 12/31/2013– 2/29/2020). Eligible individuals were ≥ 18 years of age, continuously enrolled (365 days before/after cohort entry), and had a claim for either condition. Those with cataplexy were excluded from the idiopathic hypersomnia cohort. Individuals entered cohorts upon their earliest claim for their condition during the study period. Clinical classification categories, select conditions, healthcare resource utilization (HCRU), and medical costs were assessed over a 2-year period. Percentages of individuals with comorbid conditions were summarized. Mean (SD) HCRU and total all-cause medical costs were presented per patient per year (PPPY). HCRU and medical costs PPPY were HCRU or medical costs 365 days before/after cohort entry divided by 2. Results: 11,426 individuals with idiopathic hypersomnia and 31,214 with narcolepsy were included. Median ages were 45 and 43 years, respectively; approximately 65% of each cohort was female. Mean numbers of comorbid conditions across all categories were 15.4 (5.4) and 14.6 (5.7), respectively. Ill-defined conditions (95.6%, 94.4%), nervous system diseases (83.8%, 100.0%), and respiratory system diseases (83.6%, 79.1%) were most common broad clinical classification categories. Both cohorts experienced sleep apnea (62.8%, 52.1%), hypertension (45.7%, 42.9%), hyperlipidemia (42.2%, 38.4%), pain (66.4%, 66.0%), and mood disorders (41.9%, 43.3%). Mean all-cause outpatient visits PPPY among those with ≥ 1 visit were 28.2 (40.1) and 27.4 (40.6) for individuals with idiopathic hypersomnia or narcolepsy, respectively. Mean all-cause medical costs PPPY were $11,134 ($22,674) and $11,591 ($25,956) for individuals with idiopathic hypersomnia or narcolepsy. Conclusion: Individuals with narcolepsy and idiopathic hypersomnia experience comorbid conditions which bear consequences for healthcare systems; these may be considered when evaluating overall health of individuals with either condition. Plain Language Summary: Idiopathic hypersomnia and narcolepsy are rare diseases that affect sleep. Both diseases can make people extremely sleepy throughout the day. This study used health insurance claim records to understand the effects of these diseases on patients’ health. The health insurance claims were from December 2013 to February 2020. This study looked at other diseases that people with idiopathic hypersomnia or narcolepsy have, the number of times they saw a doctor, and how much their care cost over 2 years. This study found that people with idiopathic hypersomnia or narcolepsy also have many other conditions such as problems while sleeping, diseases of the heart and blood vessels, diseases of the metabolic system (like high cholesterol), pain, and mental illness. They also visited their doctors over 25 times on average throughout the year and had medical costs totaling about $10,000 per year on average. These results show that there is a large burden of many health conditions and a need for people with either idiopathic hypersomnia or narcolepsy to see their doctors to help understand their overall health.
- 1 August 2025
- Published by Taylor & Francis in Nature and Science of Sleep
- Vol. ume 17, 1809-1823
Open AccessThe Clinical and Economic Burden of Idiopathic Hypersomnia and Narcolepsy: A United States Claims-Based Analysis
Purpose: Idiopathic hypersomnia and narcolepsy are similar but distinct sleep disorders. This study evaluated the clinical and economic burden experienced by individuals with either condition. Patients and Methods: Merative™ MarketScan® Research Databases claims were analyzed (study period, 12/31/2013– 2/29/2020). Eligible individuals were ≥ 18 years of age, continuously enrolled (365 days before/after cohort entry), and had a claim for either condition. Those with cataplexy were excluded from the idiopathic hypersomnia cohort. Individuals entered cohorts upon their earliest claim for their condition during the study period. Clinical classification categories, select conditions, healthcare resource utilization (HCRU), and medical costs were assessed over a 2-year period. Percentages of individuals with comorbid conditions were summarized. Mean (SD) HCRU and total all-cause medical costs were presented per patient per year (PPPY). HCRU and medical costs PPPY were HCRU or medical costs 365 days before/after cohort entry divided by 2. Results: 11,426 individuals with idiopathic hypersomnia and 31,214 with narcolepsy were included. Median ages were 45 and 43 years, respectively; approximately 65% of each cohort was female. Mean numbers of comorbid conditions across all categories were 15.4 (5.4) and 14.6 (5.7), respectively. Ill-defined conditions (95.6%, 94.4%), nervous system diseases (83.8%, 100.0%), and respiratory system diseases (83.6%, 79.1%) were most common broad clinical classification categories. Both cohorts experienced sleep apnea (62.8%, 52.1%), hypertension (45.7%, 42.9%), hyperlipidemia (42.2%, 38.4%), pain (66.4%, 66.0%), and mood disorders (41.9%, 43.3%). Mean all-cause outpatient visits PPPY among those with ≥ 1 visit were 28.2 (40.1) and 27.4 (40.6) for individuals with idiopathic hypersomnia or narcolepsy, respectively. Mean all-cause medical costs PPPY were $11,134 ($22,674) and $11,591 ($25,956) for individuals with idiopathic hypersomnia or narcolepsy. Conclusion: Individuals with narcolepsy and idiopathic hypersomnia experience comorbid conditions which bear consequences for healthcare systems; these may be considered when evaluating overall health of individuals with either condition. Plain Language Summary: Idiopathic hypersomnia and narcolepsy are rare diseases that affect sleep. Both diseases can make people extremely sleepy throughout the day. This study used health insurance claim records to understand the effects of these diseases on patients’ health. The health insurance claims were from December 2013 to February 2020. This study looked at other diseases that people with idiopathic hypersomnia or narcolepsy have, the number of times they saw a doctor, and how much their care cost over 2 years. This study found that people with idiopathic hypersomnia or narcolepsy also have many other conditions such as problems while sleeping, diseases of the heart and blood vessels, diseases of the metabolic system (like high cholesterol), pain, and mental illness. They also visited their doctors over 25 times on average throughout the year and had medical costs totaling about $10,000 per year on average. These results show that there is a large burden of many health conditions and a need for people with either idiopathic hypersomnia or narcolepsy to see their doctors to help understand their overall health.
- Open Access
- 1 July 2025
- Published by Taylor & Francis in Nature and Science of Sleep
- Vol. ume 17, 1743-1755
The Clinical and Economic Burden of Idiopathic Hypersomnia: Results from the Real-World Idiopathic Hypersomnia Total Health Model (RHYTHM) Study
Purpose: Limited research describes the clinical and economic burden of idiopathic hypersomnia. This study compared this burden in individuals with idiopathic hypersomnia against matched controls. Patients and Methods: This retrospective cohort study analyzed Merative™ MarketScan® US claims (12/31/2013– 2/29/2020). Individuals were ≥ 18 years of age and continuously enrolled during a 2-year assessment period. Individuals with idiopathic hypersomnia entered the cohort upon their first idiopathic hypersomnia medical claim; they were matched 1:5 with non–idiopathic hypersomnia controls on age, sex, region, insurance type, and cohort entry date. Odds of comorbid conditions experienced by individuals in either cohort during the 2-year assessment were compared. Healthcare resource utilization (HCRU) was presented as percentages by care setting. Median medical cost per patient per year (PPPY) was the sum of inpatient, outpatient, and emergency costs. P-values were not adjusted for multiplicity. Results: This analysis included 11,412 individuals with idiopathic hypersomnia and 57,058 matched controls. In both cohorts, median age was 45 years and 65% of individuals were female. Compared with matched controls, individuals with idiopathic hypersomnia had 1.6- to 4.4-fold higher odds (all P< 0.0001) of grouped conditions defined by multilevel Clinical Classifications Software categories, from neoplasms to nervous systems diseases, including sleep-related conditions. Individuals with idiopathic hypersomnia had higher odds of all comorbid conditions evaluated, including sleep-related, cardiovascular and cardiometabolic, and neuropsychiatric conditions, compared with matched controls. Individuals with idiopathic hypersomnia had higher HCRU (outpatient, 100% vs 96.1%; emergency department, 46.6% vs 34.3%; inpatient, 10.2% vs 8.5%, all P< 0.0001) than matched controls. Median medical costs PPPY were higher for individuals with idiopathic hypersomnia ($4854) than matched controls ($1348). Conclusion: Compared with matched controls, individuals with idiopathic hypersomnia had a higher clinical burden, spanning multiple organ systems, and a higher economic burden. Individuals’ clinical profiles may be considered when treating idiopathic hypersomnia and providing holistic care. Plain Language Summary: Idiopathic hypersomnia is a rare sleep disorder that can impact quality of life, work, and overall wellbeing. People with this sleep disorder are often excessively sleepy throughout the day and can sleep for over 11 hours a day. This study aimed to learn about other conditions that people with idiopathic hypersomnia are likely to have, how often they go to the doctor, and how much their healthcare costs. The study compared people with and without idiopathic hypersomnia. To compare these 2 groups, healthcare claims data (medical bill information) were used. Each person with idiopathic hypersomnia was compared with 1 or more (up to 5) people without idiopathic hypersomnia who were similar in characteristics such as age, sex, where they lived, and their type of health insurance. The study found that people with idiopathic hypersomnia are more likely to have other medical conditions, such as brain and nerve diseases, heart-related diseases, and mental illnesses; see their doctors more often; and have higher medical costs than people without idiopathic hypersomnia. These results are important because they raise awareness around the hardship faced by people who have this rare sleep disorder and help doctors understand their needs.
- 1 July 2025
- Published by Taylor & Francis in Nature and Science of Sleep
- Vol. ume 17, 1743-1755
Open AccessThe Clinical and Economic Burden of Idiopathic Hypersomnia: Results from the Real-World Idiopathic Hypersomnia Total Health Model (RHYTHM) Study
Purpose: Limited research describes the clinical and economic burden of idiopathic hypersomnia. This study compared this burden in individuals with idiopathic hypersomnia against matched controls. Patients and Methods: This retrospective cohort study analyzed Merative™ MarketScan® US claims (12/31/2013– 2/29/2020). Individuals were ≥ 18 years of age and continuously enrolled during a 2-year assessment period. Individuals with idiopathic hypersomnia entered the cohort upon their first idiopathic hypersomnia medical claim; they were matched 1:5 with non–idiopathic hypersomnia controls on age, sex, region, insurance type, and cohort entry date. Odds of comorbid conditions experienced by individuals in either cohort during the 2-year assessment were compared. Healthcare resource utilization (HCRU) was presented as percentages by care setting. Median medical cost per patient per year (PPPY) was the sum of inpatient, outpatient, and emergency costs. P-values were not adjusted for multiplicity. Results: This analysis included 11,412 individuals with idiopathic hypersomnia and 57,058 matched controls. In both cohorts, median age was 45 years and 65% of individuals were female. Compared with matched controls, individuals with idiopathic hypersomnia had 1.6- to 4.4-fold higher odds (all P< 0.0001) of grouped conditions defined by multilevel Clinical Classifications Software categories, from neoplasms to nervous systems diseases, including sleep-related conditions. Individuals with idiopathic hypersomnia had higher odds of all comorbid conditions evaluated, including sleep-related, cardiovascular and cardiometabolic, and neuropsychiatric conditions, compared with matched controls. Individuals with idiopathic hypersomnia had higher HCRU (outpatient, 100% vs 96.1%; emergency department, 46.6% vs 34.3%; inpatient, 10.2% vs 8.5%, all P< 0.0001) than matched controls. Median medical costs PPPY were higher for individuals with idiopathic hypersomnia ($4854) than matched controls ($1348). Conclusion: Compared with matched controls, individuals with idiopathic hypersomnia had a higher clinical burden, spanning multiple organ systems, and a higher economic burden. Individuals’ clinical profiles may be considered when treating idiopathic hypersomnia and providing holistic care. Plain Language Summary: Idiopathic hypersomnia is a rare sleep disorder that can impact quality of life, work, and overall wellbeing. People with this sleep disorder are often excessively sleepy throughout the day and can sleep for over 11 hours a day. This study aimed to learn about other conditions that people with idiopathic hypersomnia are likely to have, how often they go to the doctor, and how much their healthcare costs. The study compared people with and without idiopathic hypersomnia. To compare these 2 groups, healthcare claims data (medical bill information) were used. Each person with idiopathic hypersomnia was compared with 1 or more (up to 5) people without idiopathic hypersomnia who were similar in characteristics such as age, sex, where they lived, and their type of health insurance. The study found that people with idiopathic hypersomnia are more likely to have other medical conditions, such as brain and nerve diseases, heart-related diseases, and mental illnesses; see their doctors more often; and have higher medical costs than people without idiopathic hypersomnia. These results are important because they raise awareness around the hardship faced by people who have this rare sleep disorder and help doctors understand their needs.
- 5 July 2024
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 194 (2) , 362-369
Caregiver burden and risk of epithelial ovarian cancer in the Nurses’ Health Studies
Psychosocial stress may increase ovarian cancer risk and accelerate disease progression. We examined the association between caregiver burden, a common stressor, and risk of epithelial ovarian cancer. We prospectively followed 67 724 women in the Nurses’ Health Study (1992-2012) and 70 720 women in the Nurses’ Health Study II (2001-2009) who answered questions on informal caregiving (ie, caregiving outside of work). Women who reported no informal caregiving were considered noncaregivers, while, among women who provided care outside of work, caregiver burden was categorized by time spent caregiving and perceived stress from caregiving. For the 34% of women who provided informal care for ≥15 hours per week, 42% described caregiving as moderately to extremely stressful. Pooled multivariate analyses indicated no difference in ovarian cancer risk for women providing ≥15 hours of care per week compared to noncaregivers (hazard ratio [HR] = 0.96; 95% confidence interval [CI], 0.79-1.18), and no association was evident for women who reported moderate or extreme stress from caregiving compared to noncaregivers (HR = 0.96; 95% CI, 0.75-1.22). Together with prior work evaluating job strain and ovarian cancer risk, our findings suggest that, when evaluating a stressor’s role in cancer risk, it is critical to consider how the stressor contributes to the overall experience of distress. This article is part of a Special Collection on Gynecological Cancer.
- 5 July 2024
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 194 (2) , 362-369
Caregiver burden and risk of epithelial ovarian cancer in the Nurses’ Health Studies
Psychosocial stress may increase ovarian cancer risk and accelerate disease progression. We examined the association between caregiver burden, a common stressor, and risk of epithelial ovarian cancer. We prospectively followed 67 724 women in the Nurses’ Health Study (1992-2012) and 70 720 women in the Nurses’ Health Study II (2001-2009) who answered questions on informal caregiving (ie, caregiving outside of work). Women who reported no informal caregiving were considered noncaregivers, while, among women who provided care outside of work, caregiver burden was categorized by time spent caregiving and perceived stress from caregiving. For the 34% of women who provided informal care for ≥15 hours per week, 42% described caregiving as moderately to extremely stressful. Pooled multivariate analyses indicated no difference in ovarian cancer risk for women providing ≥15 hours of care per week compared to noncaregivers (hazard ratio [HR] = 0.96; 95% confidence interval [CI], 0.79-1.18), and no association was evident for women who reported moderate or extreme stress from caregiving compared to noncaregivers (HR = 0.96; 95% CI, 0.75-1.22). Together with prior work evaluating job strain and ovarian cancer risk, our findings suggest that, when evaluating a stressor’s role in cancer risk, it is critical to consider how the stressor contributes to the overall experience of distress. This article is part of a Special Collection on Gynecological Cancer.
- Open Access
- 1 August 2020
- Published by Elsevier in Reproductive Toxicology
- Vol. 95, 45-50
Pregnancy outcomes in patients treated with leflunomide, the parent compound of the multiple sclerosis drug teriflunomide
- 1 August 2020
- Published by Elsevier in Reproductive Toxicology
- Vol. 95, 45-50
Open AccessPregnancy outcomes in patients treated with leflunomide, the parent compound of the multiple sclerosis drug teriflunomide
- Open Access
A prospective analysis of circulating plasma metabolomics and ovarian cancer risk
We assessed the association of pre-diagnostic plasma metabolites (N=420) with ovarian cancer risk. We included 252 cases and 252 matched controls from the Nurses’ Health Studies. Multivariable logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) comparing the 90 th -10 th percentile in metabolite levels, using permutation tests to account for testing multiple correlated hypotheses. Weighted gene co-expression network analysis (WGCNA) modules (n=10) and metabolite set enrichment analysis (MSEA; n=23) were also evaluated. Pseudouridine had the strongest statistical association with ovarian cancer risk overall (OR=2.56, 95%CI=1.48-4.45; p=0.001/adjusted-p=0.15). C36:2 phosphatidylcholine (PC) plasmalogen had the strongest statistical association with lower risk (OR=0.11, 95%CI=0.03-0.35; p<0.001/adjusted-p=0.06) and pseudouridine with higher risk (OR=9.84, 95%CI=2.89-37.82; p<0.001/adjusted-p=0.07) of non-serous tumors. Seven WGCNA modules and 15 classes were associated with risk at FDR≤0.20. Triacylglycerols (TAGs) showed heterogeneity by tumor aggressiveness (case-only heterogeneity-p<0.0001). TAG association with risk overall and serous tumors differed by acyl carbon content and saturation. Pseudouridine may be a novel risk factor for ovarian cancer. TAGs may also be important, particularly for rapidly fatal tumors, with associations differing by structural features. Validation in independent prospective studies and complementary experimental work to understand biological mechanisms is needed.
Open AccessA prospective analysis of circulating plasma metabolomics and ovarian cancer risk
We assessed the association of pre-diagnostic plasma metabolites (N=420) with ovarian cancer risk. We included 252 cases and 252 matched controls from the Nurses’ Health Studies. Multivariable logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) comparing the 90 th -10 th percentile in metabolite levels, using permutation tests to account for testing multiple correlated hypotheses. Weighted gene co-expression network analysis (WGCNA) modules (n=10) and metabolite set enrichment analysis (MSEA; n=23) were also evaluated. Pseudouridine had the strongest statistical association with ovarian cancer risk overall (OR=2.56, 95%CI=1.48-4.45; p=0.001/adjusted-p=0.15). C36:2 phosphatidylcholine (PC) plasmalogen had the strongest statistical association with lower risk (OR=0.11, 95%CI=0.03-0.35; p<0.001/adjusted-p=0.06) and pseudouridine with higher risk (OR=9.84, 95%CI=2.89-37.82; p<0.001/adjusted-p=0.07) of non-serous tumors. Seven WGCNA modules and 15 classes were associated with risk at FDR≤0.20. Triacylglycerols (TAGs) showed heterogeneity by tumor aggressiveness (case-only heterogeneity-p<0.0001). TAG association with risk overall and serous tumors differed by acyl carbon content and saturation. Pseudouridine may be a novel risk factor for ovarian cancer. TAGs may also be important, particularly for rapidly fatal tumors, with associations differing by structural features. Validation in independent prospective studies and complementary experimental work to understand biological mechanisms is needed.
- Open Access
- 1 October 2018
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 73 (10) , 576-578
Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium
(Abstracted from J Natl Cancer Inst 2018; doi: 10.1093/jnci/djy100) The most fatal gynecologic cancer is ovarian cancer. This is largely due to its delayed symptom presentation and lack of early detection strategies.
- 1 October 2018
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 73 (10) , 576-578
Open AccessAnalgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium
(Abstracted from J Natl Cancer Inst 2018; doi: 10.1093/jnci/djy100) The most fatal gynecologic cancer is ovarian cancer. This is largely due to its delayed symptom presentation and lack of early detection strategies.
- Open Access
- 21 August 2018
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (9) , 2473
rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology
Thymidylate synthase (TYMS) is a crucial enzyme for DNA synthesis. TYMS expression is regulated by its antisense mRNA, ENOSF1. Disrupted regulation may promote uncontrolled DNA synthesis and tumor growth. We sought to replicate our previously reported association between rs495139 in the TYMS-ENOSF1 3′ gene region and increased risk of mucinous ovarian carcinoma (MOC) in an independent sample. Genotypes from 24,351 controls to 15,000 women with invasive OC, including 665 MOC, were available. We estimated per-allele odds ratios (OR) and 95% confidence intervals (CI) using unconditional logistic regression, and meta-analysis when combining these data with our previous report. The association between rs495139 and MOC was not significant in the independent sample (OR = 1.09; 95% CI = 0.97–1.22; p = 0.15; N = 665 cases). Meta-analysis suggested a weak association (OR = 1.13; 95% CI = 1.03–1.24; p = 0.01; N = 1019 cases). No significant association with risk of other OC histologic types was observed (p = 0.05 for tumor heterogeneity). In expression quantitative trait locus (eQTL) analysis, the rs495139 allele was positively associated with ENOSF1 mRNA expression in normal tissues of the gastrointestinal system, particularly esophageal mucosa (r = 0.51, p = 1.7 × 10−28), and nonsignificantly in five MOC tumors. The association results, along with inconclusive tumor eQTL findings, suggest that a true effect of rs495139 might be small.
- 21 August 2018
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (9) , 2473
Open Accessrs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology
Thymidylate synthase (TYMS) is a crucial enzyme for DNA synthesis. TYMS expression is regulated by its antisense mRNA, ENOSF1. Disrupted regulation may promote uncontrolled DNA synthesis and tumor growth. We sought to replicate our previously reported association between rs495139 in the TYMS-ENOSF1 3′ gene region and increased risk of mucinous ovarian carcinoma (MOC) in an independent sample. Genotypes from 24,351 controls to 15,000 women with invasive OC, including 665 MOC, were available. We estimated per-allele odds ratios (OR) and 95% confidence intervals (CI) using unconditional logistic regression, and meta-analysis when combining these data with our previous report. The association between rs495139 and MOC was not significant in the independent sample (OR = 1.09; 95% CI = 0.97–1.22; p = 0.15; N = 665 cases). Meta-analysis suggested a weak association (OR = 1.13; 95% CI = 1.03–1.24; p = 0.01; N = 1019 cases). No significant association with risk of other OC histologic types was observed (p = 0.05 for tumor heterogeneity). In expression quantitative trait locus (eQTL) analysis, the rs495139 allele was positively associated with ENOSF1 mRNA expression in normal tissues of the gastrointestinal system, particularly esophageal mucosa (r = 0.51, p = 1.7 × 10−28), and nonsignificantly in five MOC tumors. The association results, along with inconclusive tumor eQTL findings, suggest that a true effect of rs495139 might be small.
- Open Access
Social integration and survival after diagnosis of colorectal cancer
BACKGROUND: Although larger social networks have been associated with lower all‐cause mortality, few studies have examined whether social integration predicts survival outcomes among patients with colorectal cancer (CRC). The authors examined the association between social ties and survival after CRC diagnosis in a prospective cohort study.METHODS: Participants included 896 women in the Nurses' Health Study who were diagnosed with stage I, II, or III CRC between 1992 and 2012. Stage was assigned using the American Joint Committee on Cancer criteria. Social integration was assessed every 4 years since 1992 using the Berkman‐Syme Social Network Index, which included marital status, social network size, contact frequency, religious participation, and other social group participation.RESULTS: During follow‐up, there were 380 total deaths, 167 of which were due to CRC. In multivariable analyses, women who were socially integrated before diagnosis had a subsequent reduced risk of all‐cause mortality (hazard ratio [HR], 0.65; 95% confidence interval [95% CI], 0.46‐0.92) and CRC mortality (HR, 0.63; 95% CI, 0.38‐1.06) compared with women who were socially isolated. In particular, women with more intimate ties (family and friends) had lower all‐cause mortality (HR, 0.61; 95% CI, 0.42‐0.88) and CRC mortality (HR, 0.59; 95% CI, 0.34‐1.03) compared with those with few intimate ties. Participation in religious or community activities was not found to be related to outcomes. The analysis of postdiagnosis social integration yielded similar results.CONCLUSIONS: Socially integrated women were found to have better survival after a diagnosis of CRC, possibly due to beneficial caregiving from their family and friends. Interventions aimed at strengthening social network structures to ensure access to care may be valuable programmatic tools in the management of patients with CRC. Cancer 2018;124:833‐40. © 2017 American Cancer Society.
Open AccessSocial integration and survival after diagnosis of colorectal cancer
BACKGROUND: Although larger social networks have been associated with lower all‐cause mortality, few studies have examined whether social integration predicts survival outcomes among patients with colorectal cancer (CRC). The authors examined the association between social ties and survival after CRC diagnosis in a prospective cohort study.METHODS: Participants included 896 women in the Nurses' Health Study who were diagnosed with stage I, II, or III CRC between 1992 and 2012. Stage was assigned using the American Joint Committee on Cancer criteria. Social integration was assessed every 4 years since 1992 using the Berkman‐Syme Social Network Index, which included marital status, social network size, contact frequency, religious participation, and other social group participation.RESULTS: During follow‐up, there were 380 total deaths, 167 of which were due to CRC. In multivariable analyses, women who were socially integrated before diagnosis had a subsequent reduced risk of all‐cause mortality (hazard ratio [HR], 0.65; 95% confidence interval [95% CI], 0.46‐0.92) and CRC mortality (HR, 0.63; 95% CI, 0.38‐1.06) compared with women who were socially isolated. In particular, women with more intimate ties (family and friends) had lower all‐cause mortality (HR, 0.61; 95% CI, 0.42‐0.88) and CRC mortality (HR, 0.59; 95% CI, 0.34‐1.03) compared with those with few intimate ties. Participation in religious or community activities was not found to be related to outcomes. The analysis of postdiagnosis social integration yielded similar results.CONCLUSIONS: Socially integrated women were found to have better survival after a diagnosis of CRC, possibly due to beneficial caregiving from their family and friends. Interventions aimed at strengthening social network structures to ensure access to care may be valuable programmatic tools in the management of patients with CRC. Cancer 2018;124:833‐40. © 2017 American Cancer Society.
- 15 March 2017
- Published by Springer Nature in Cancer Causes & Control
- Vol. 28 (5) , 437-445
Endometriosis and risk of ovarian and endometrial cancers in a large prospective cohort of U.S. nurses
Purpose Endometriosis is associated with ovarian cancer, but the relation with endometrial cancer is unclear. Prior studies generally were retrospective and had potential limitations, including use of self-reported endometriosis, failure to account for delays between symptom onset and endometriosis diagnosis, and changes in risk factors post-endometriosis diagnosis. We evaluated whether these limitations obscured a weak association with endometrial cancer and the extent to which these limitations impacted associations with ovarian cancer. Methods Cox proportional hazards regression models were used to assess associations between endometriosis and cancer risk, evaluating the impacts of self-reported vs. laparoscopically confirmed endometriosis, delayed diagnosis, and post-endometriosis diagnosis changes in risk factor exposures on relative risk estimates. Results Over 18 years of follow-up, we identified 228 ovarian and 166 endometrial cancers among 102,025 and 97,109 eligible women, respectively. Self-reported endometriosis was associated with ovarian cancer [relative risk (RR): 1.81; 95% confidence interval (CI): 1.26–2.58]; this association was stronger for laparoscopically confirmed endometriosis (HR: 2.14; 95% CI 1.45–3.15). No association was observed with endometrial cancer (self-report RR: 0.78; 95% CI 0.42–1.44; laparoscopic-confirmation RR: 0.76; 95% CI 0.35–1.64). Accounting for diagnosis delays or post-endometriosis diagnosis changes in risk factors had a little impact. Conclusions This study adds to the evidence that endometriosis is not strongly linked to endometrial cancer risk and that the association with ovarian cancer is robust to misclassification, diagnostic delay, and changes in exposures post-endometriosis diagnosis. Our analysis suggests that confounding and misclassification do not obscure a weak association for endometrial cancer risk, although our results should be replicated.
- 15 March 2017
- Published by Springer Nature in Cancer Causes & Control
- Vol. 28 (5) , 437-445
Endometriosis and risk of ovarian and endometrial cancers in a large prospective cohort of U.S. nurses
Purpose Endometriosis is associated with ovarian cancer, but the relation with endometrial cancer is unclear. Prior studies generally were retrospective and had potential limitations, including use of self-reported endometriosis, failure to account for delays between symptom onset and endometriosis diagnosis, and changes in risk factors post-endometriosis diagnosis. We evaluated whether these limitations obscured a weak association with endometrial cancer and the extent to which these limitations impacted associations with ovarian cancer. Methods Cox proportional hazards regression models were used to assess associations between endometriosis and cancer risk, evaluating the impacts of self-reported vs. laparoscopically confirmed endometriosis, delayed diagnosis, and post-endometriosis diagnosis changes in risk factor exposures on relative risk estimates. Results Over 18 years of follow-up, we identified 228 ovarian and 166 endometrial cancers among 102,025 and 97,109 eligible women, respectively. Self-reported endometriosis was associated with ovarian cancer [relative risk (RR): 1.81; 95% confidence interval (CI): 1.26–2.58]; this association was stronger for laparoscopically confirmed endometriosis (HR: 2.14; 95% CI 1.45–3.15). No association was observed with endometrial cancer (self-report RR: 0.78; 95% CI 0.42–1.44; laparoscopic-confirmation RR: 0.76; 95% CI 0.35–1.64). Accounting for diagnosis delays or post-endometriosis diagnosis changes in risk factors had a little impact. Conclusions This study adds to the evidence that endometriosis is not strongly linked to endometrial cancer risk and that the association with ovarian cancer is robust to misclassification, diagnostic delay, and changes in exposures post-endometriosis diagnosis. Our analysis suggests that confounding and misclassification do not obscure a weak association for endometrial cancer risk, although our results should be replicated.